Victor Sandor
Director/Board Member bei MERUS N.V.
Vermögen: 261 969 $ am 31.03.2024
Aktive Positionen von Victor Sandor
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MERUS N.V. | Director/Board Member | 12.06.2019 | - |
Independent Dir/Board Member | 12.06.2019 | - | |
ADC THERAPEUTICS SA | Director/Board Member | 27.04.2020 | - |
Independent Dir/Board Member | 27.04.2020 | - | |
PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 01.05.2020 | - |
Independent Dir/Board Member | - | - | |
KYMERA THERAPEUTICS, INC. | Director/Board Member | 03.11.2022 | - |
Independent Dir/Board Member | 03.11.2022 | - | |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01.07.2019 | - |
Karriereverlauf von Victor Sandor
Ehemalige bekannte Positionen von Victor Sandor
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01.01.2010 | 01.09.2019 |
ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 22.09.2014 | 01.08.2019 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01.02.2010 | 01.09.2014 |
Ausbildung von Victor Sandor
McGill University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Kanada | 2 |
Niederlande | 2 |
Operativ
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sektoral
Health Technology | 9 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
INCYTE CORPORATION | Health Technology |
MERUS N.V. | Health Technology |
ADC THERAPEUTICS SA | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Börse
- Insiders
- Victor Sandor
- Erfahrung